JPRN-UMIN000028599已完成1 期
Phase I study for the safety of soy milk yoghurt feeding therapy in the patients with food allergy - Phase I study for yoghurt therapy of filament Lactobacilus.
Department of Dermalogy Shimane university, Faculty of Medicine0 个研究点目标入组 12 人开始时间: 2017年8月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Safety/toxicity evaluation of a new Ayurveda drug formulation Sudarshana SuspensioFever (proposed indication)SLCTR/2015/005HETC Project, Ministry of Higher Education
招募中
1 期
A Phase I/II trial to determine the Safety, Toxicity and Efficacy of Iodine-131-Rituximab and the Histone Deacetylase Inhibitor Panobinostat in Relapsed and Refractory Indolent B-cell LymphomaRelapsed and Refractory Indolent B-cell LymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaACTRN12612000746831Peter MacCallum Cancer Centre30
终止
1 期
This study is examining the safety and tolerability of a new drug (Everolimus) in combination with chemotherapy in the treatment of relapsed adult acute lymphobastic leukaemiaacute lymphobastic leukaemia (ALL)Cancer - Leukaemia - Acute leukaemiaACTRN12610000405011Australasian Leukaemia and Lymphoma Group20
进行中（未招募）
不适用
Phase II pilot study on safety of administration of 3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment ( day 50-8th Week) of AmBisome in antifungal primary prophylaxis treatment of high risk patients undergoing allogeneic stem-cell transplantation - ProphessorEUCTR2004-003745-40-ITGILEAD SCIENCES S.R.L.
已完成
不适用
WT1 TCR gene therapy for leukaemia: a phase I/II safety and toxicity study (WT1 TCR-001)CancerISRCTN11622375niversity College London (UCL) (UK)7